SynthesisPloS one2025
Strategies for assessing and preventing cardiovascular disease risk in inflammatory bowel disease patients: A meta-analysis and meta-regression and bibliometric review.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Metabolic Complications in Autoimmune and Autoinflammatory Diseases: Pathophysiology, Clinical Implications, and Therapeutic Perspectives.Journal of clinical medicine · 2026Review
- Redox Homeostasis as a Therapeutic Target in Chronic Oxidative Diseases: Implications for Cancer Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue.Frontiers in endocrinology · 2026Review
- The Gut Microbial Metabolite Indole-3-Acetic Acid Reprograms Systemic Homeostasis and Ameliorates IBD-Associated Cachexia Independent of Food Intake.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate how inflammatory bowel disease in adults increases the risk of developing cardiovascular disease.
designMeta-analysis, meta-regression and bibliometric review. DATA SOURCES: PubMed and Embase were searched from their inception until December 19, 2024. Additionally, a manual search was conducted to identify cohort studies and related systematic reviews. Web of Science Core Collection (WoSCC) database was used to bibliometric analysis. ELIGIBILITY CRITERIA: Cohort studies assessing the risk of cardiovascular disease (CVD) in adults with inflammatory bowel disease (IBD) were included. Non inflammatory bowel disease exposure was considered as the control group. The risk of bias and the certainty of the evidence were evaluated. Meta analysis, meta regression, sensitivity analysis, and bibliometric analysis of keywords were performed.
results23 studies, comprising 20 different samples (n=45,887,104), were included. meta-analyses showed adults with IBD regardless of Crohn's disease and ulcerative colitis increased the CVD risk. This risk increased in IBD patients after conducting sensitivity analyses. However, the strength of evidence was deemed very low for all outcomes with substantial heterogeneity observed across all outcomes. The bibliometric review showed the neutrophil-to-lymphocyte ratio can act as a biomarker for predicting IBD severity.
conclusionWhile inflammatory bowel disease (IBD) may elevate the risk of cardiovascular disease (CVD), current evidence does not support the use of medication for primary prevention. Randomized controlled trials are needed to address this gap in knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.